Results 71 to 80 of about 7,681 (165)

Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women [PDF]

, 2009
To compare single- and multiple-dose maraviroc exposures in cervicovaginal fluid (CVF) and vaginal tissue (VT) with blood plasma (BP) and quantify maraviroc protein binding in ...
Andrews, Emma, Worsley, Jochen, Patterson, Kristine B, Werner, Rebecca E, Dumond, Julie B, Pecha, Allison L, Damle, Bharat, Kashuba, Angela D M, Tressler, Randall   +8 more
core   +1 more source

Maternal-Fetal Pharmacokinetics and Dynamics of a Single Intrapartum Dose of Maraviroc in Rhesus Macaques [PDF]

, 2010
Single-dose nevirapine (NVP) is effective in reducing mother-to-child transmission (MTCT) of HIV; however, the subsequent development of drug resistance is problematic.
Mark A. Winters, Angela D. M. Kashuba, Nancy S. Shulman, Kashuba, A. D. M., Van Rompay, K. K. A., Winters, M. A., Mark Holodniy, Shulman, N. S., Koen K. A. Van Rompay, Holodniy, M.   +9 more
core   +1 more source

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study

Microbiology Spectrum
The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical strains, representative of the viral genetic ...
Ségolène Gracias, Ikrame El Yaalaoui, Benoît Visseaux, Charlotte Charpentier, Diane Descamps, Charlène Martin, Fanny Lermechain, Jean-Christophe Plantier, Elodie Alessandri-Gradt   +8 more
doaj   +1 more source

Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

PLoS ONE, 2013
BackgroundImmunological non-responders (INRs) lacked CD4 increase despite HIV-viremia suppression on HAART and had an increased risk of disease progression.
Stefano Rusconi, Paola Vitiello, Fulvio Adorni, Elisa Colella, Emanuele Focà, Amedeo Capetti, Paola Meraviglia, Clara Abeli, Stefano Bonora, Marco D'Annunzio, Antonio Di Biagio, Massimo Di Pietro, Luca Butini, Giancarlo Orofino, Manuela Colafigli, Gabriella d'Ettorre, Daniela Francisci, Giustino Parruti, Alessandro Soria, Anna Rita Buonomini, Chiara Tommasi, Silvia Mosti, Francesca Bai, Silvia Di Nardo Stuppino, Manuela Morosi, Marco Montano, Pamela Tau, Esther Merlini, Giulia Marchetti   +28 more
doaj   +1 more source

HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis

AIDS Research and Therapy, 2020
Background Entry inhibitors, such as Maraviroc, hold promise as components of HIV treatment and/or pre-exposure prophylaxis in Africa. Maraviroc inhibits the interaction between HIV Envelope gp120 V3-loop and CCR5 coreceptor. HIV-1 subtype C (HIV-1-C) is
Nontokozo D. Matume, Denis M. Tebit, Pascal O. Bessong   +2 more
doaj   +1 more source

HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
ABSTRACT The study assessed the phenotypic susceptibility of non group‐M human immunodeficiency virus type 1 (HIV‐1/non‐M) clinical isolates to ibalizumab, the first‐in‐class long‐acting CD4‐directed post‐attachment inhibitor. Thirty isolates were tested: 1 HIV‐1/M (reference strain BRU.HXB2), 2 HIV‐1/N, 26 HIV‐1/O and 1 HIV‐1/P.
Lucie Poisson, Quentin Le Hingrat, Fanny Lermechain, Fabienne Tombette, Henri Jullien, Jean‐Christophe Plantier, Elodie Alessandri‐Gradt   +6 more
wiley   +1 more source

Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques

, 2013
Objectives: To investigate the pharmacokinetics (PK) of maraviroc, a CCR5-targeted HIV-1 entry inhibitor, in rhesus macaques following vaginal administration of various maraviroc-loaded aqueous hydroxyethylcellulose (HEC) gels, and to correlate the PK ...
Forbes, Claire J., Moore, John P., Klasse, Per Johan, Goldman, Laurie, Veazey, Ronald S., Geer, Leslie, Malcolm, R. Karl; id_orcid   +6 more
core   +1 more source

Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.

PLoS ONE, 2013
Maraviroc, an (HIV-1) entry inhibitor, binds to CCR5 and efficiently prevents R5 human immunodeficiency virus type 1 (HIV-1) from using CCR5 as a coreceptor for entry into CD4(+) cells.
Yuzhe Yuan, Masaru Yokoyama, Yosuke Maeda, Hiromi Terasawa, Shinji Harada, Hironori Sato, Keisuke Yusa   +6 more
doaj   +1 more source

Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations [PDF]

, 2010
Maraviroc is an orally available antagonist of the CCR5 chemokine receptor, which acts as a human immunodeficiency virus type 1 (HIV-1) coreceptor. Binding of maraviroc to this receptor blocks HIV-1 attachment to the coreceptor and prevents HIV-1 from ...
キノシタ, エリ, カネダ, ツグヒロ, Kaneda, Tsuguhiro, Hirano, Atsushi, Kinoshita, Eri, Okubo, Nami, Takahashi, Masaaki, ノムラ, トシハル, Nomura, Toshiharu, タカハシ, マサアキ, オオクボ, ナミ, ヒラノ, アツシ   +11 more
core